Summary

The Assisted Reproductive Technology (ART) Analysis in the United States is undergoing rapid transformation, fueled by rising infertility rates, continuous technological advancements, and a broader acceptance of fertility treatments. ART procedures, including in vitro fertilization (IVF) and artificial insemination, are becoming increasingly mainstream, offering hope to individuals and couples struggling with conception. The market is expected to witness significant growth, reaching a valuation of US$4.7 Bn by 2025, and expanding further to US$14.98 Bn by 2032, registering a strong CAGR of 18.01% from 2024 to 2032.

Market Insights

Assisted reproductive technologies have revolutionized the way fertility issues are addressed. These techniques involve the manipulation of eggs, sperm, or embryos to assist individuals in achieving pregnancy. IVF remains the most dominant and widely adopted ART procedure due to its higher success rates and constant technological evolution.

In recent years, growing public awareness, improved access to treatment, and ongoing medical innovation have paved the way for an expanded ART market in the US. Technologies such as preimplantation genetic testing, embryo cryopreservation, and advanced sperm selection methods have enhanced the efficiency and success of ART procedures.

Market Drivers

A significant factor driving market growth is the rising prevalence of infertility across the US. Lifestyle changes, including increased stress, sedentary routines, and rising obesity rates, are contributing to a growing number of individuals facing fertility challenges. Research indicates that infertility affects both men and women, with a notable percentage of the population within reproductive age experiencing difficulties in conceiving.

Government initiatives and support from non-profit organizations are also making fertility treatments more accessible. These efforts aim to improve awareness, reduce stigma, and enhance affordability through financial aid and insurance support, thereby increasing the number of individuals seeking ART procedures.

Another key driver is the advancement in fertility treatment technologies. Integration of artificial intelligence (AI) in reproductive medicine is enabling more precise embryo selection, improved treatment planning, and increased success rates. AI tools help physicians evaluate embryo viability and customize therapies to individual needs, resulting in better outcomes and reduced need for multiple treatment cycles.

Business Opportunities

The ART market presents significant opportunities, particularly in areas such as fertility preservation and male infertility treatment. An increasing number of young women and cancer patients are opting to preserve their fertility for future use. Moreover, the growing awareness of male infertility has shifted the focus toward developing specialized treatments and diagnostics for men.

With greater social acceptance and a rise in demand for personalized reproductive care, fertility service providers, clinics, and technology developers are poised to benefit from expanding consumer interest and investment in this domain.

Regional Outlook

The United States remains a leader in ART adoption, supported by advanced medical facilities, skilled professionals, and a growing number of fertility centers. Urban regions, in particular, are witnessing accelerated growth due to higher awareness levels and access to cutting-edge technologies.

Efforts to improve healthcare access in suburban and rural areas are also underway, creating new growth avenues for ART providers. Additionally, insurance coverage for fertility treatments is gradually becoming more inclusive, helping reduce the financial burden on patients and promoting wider adoption.

Challenges

Despite promising growth, the ART market faces several hurdles. High treatment costs continue to be a major barrier, especially for individuals without adequate insurance coverage. ART procedures require expensive medications, advanced lab equipment, and highly trained professionals, all of which contribute to the overall cost.

Moreover, health risks associated with ART, such as multiple pregnancies, low birth weight, and ovarian hyperstimulation syndrome (OHSS), raise concerns about patient safety. These potential complications necessitate thorough medical assessment and improved procedural safety to ensure positive outcomes.

Future Outlook

Looking ahead, the future of the US ART market is optimistic. Awareness about infertility treatments is on the rise, and social acceptance is fostering a supportive environment for those seeking medical assistance. Couples are now more proactive in addressing fertility challenges, and male infertility is receiving much-needed attention.

Emerging technologies such as AI, machine learning, and genetic testing are set to further enhance the precision and efficiency of ART procedures. As these technologies become more integrated into routine practice, the success rates and affordability of treatments are expected to improve, attracting a larger patient base.

Key Companies

The US ART market is characterized by intense competition and a strong emphasis on innovation. Leading fertility centers and institutions are investing heavily in research and technology to offer better outcomes and enhanced patient care. Notable players in the market include:

• The Fertility Institutes

• Shady Grove Fertility

• Pacific Fertility Centre

• Boston IVF

• Cleveland Clinic Fertility Centre

• Reproductive Medicine Associates of New Jersey (RMANJ)

• Columbia University Fertility Centre

• Mayo Clinic Fertility Centre

• Texas Fertility Centre

• UCSF Centre for Reproductive Health

These organizations continue to push the boundaries of reproductive medicine by expanding service portfolios and improving treatment experiences.

Recent Developments

• January 2024: Ivy Fertility partnered with SMP Pharmacy Solutions to enhance the patient experience across 13 fertility locations in the US.

• February 2023: Bumrungrad International Hospital launched a comprehensive Fertility Centre & IVF Clinic to provide end-to-end reproductive care.

• October 2023: Hamilton Thorne Ltd. acquired Genetics Medical Products and Genetics Services, bolstering its portfolio of IVF devices and technology solutions.

US Assisted Reproductive Technology Market Segmentation

By Technique

• In Vitro Fertilization (IVF)

• Artificial Insemination

By Procedure

• Fresh Donor

• Fresh Non-Donor

• Frozen Donor

• Frozen Non-Donor

By End Use

• Fertility Clinics

• Hospitals

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. U.S. Assisted Reproductive Technology Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. U.S. Assisted Reproductive Technology Market Outlook, 2019-2032
3.1. U.S. Assisted Reproductive Technology Market Outlook, by Technique, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. IVF
3.1.1.2. Artificial Insemination
3.2. U.S. Assisted Reproductive Technology Market Outlook, by Procedure, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Fresh Donor
3.2.1.2. Fresh non-Donor
3.2.1.3. Frozen Donor
3.2.1.4. Frozen non-Donor
3.3. U.S. Assisted Reproductive Technology Market Outlook, by End Use, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Fertility Clinics
3.3.1.2. Hospitals
4. Competitive Landscape
4.1. By Technique vs by Procedure Heatmap
4.2. Company Market Share Analysis, 2025
4.3. Competitive Dashboard
4.4. Company Profiles
4.4.1. The Fertility Institutes
4.4.1.1. Company Overview
4.4.1.2. Product Portfolio
4.4.1.3. Financial Overview
4.4.1.4. Business Strategies and Development
4.4.2. Shady Grove Fertility
4.4.2.1. Company Overview
4.4.2.2. Product Portfolio
4.4.2.3. Financial Overview
4.4.2.4. Business Strategies and Development
4.4.3. Pacific Fertility Centre
4.4.3.1. Company Overview
4.4.3.2. Product Portfolio
4.4.3.3. Financial Overview
4.4.3.4. Business Strategies and Development
4.4.4. Boston IVF
4.4.4.1. Company Overview
4.4.4.2. Product Portfolio
4.4.4.3. Financial Overview
4.4.4.4. Business Strategies and Development
4.4.5. Cleveland Clinic Fertility Centre
4.4.5.1. Company Overview
4.4.5.2. Product Portfolio
4.4.5.3. Financial Overview
4.4.5.4. Business Strategies and Development
4.4.6. Reproductive Medicine Associates of New Jersey (RMANJ)
4.4.6.1. Company Overview
4.4.6.2. Product Portfolio
4.4.6.3. Financial Overview
4.4.6.4. Business Strategies and Development
4.4.7. Columbia University Fertility Centre
4.4.7.1. Company Overview
4.4.7.2. Product Portfolio
4.4.7.3. Financial Overview
4.4.7.4. Business Strategies and Development
4.4.8. Mayo Clinic Fertility Centre
4.4.8.1. Company Overview
4.4.8.2. Product Portfolio
4.4.8.3. Financial Overview
4.4.8.4. Business Strategies and Development
4.4.9. Texas Fertility Centre
4.4.9.1. Company Overview
4.4.9.2. Product Portfolio
4.4.9.3. Financial Overview
4.4.9.4. Business Strategies and Development
4.4.10. UCSF Centre for Reproductive Health
4.4.10.1. Company Overview
4.4.10.2. Product Portfolio
4.4.10.3. Financial Overview
4.4.10.4. Business Strategies and Development
5. Appendix
5.1. Research Methodology
5.2. Report Assumptions
5.3. Acronyms and Abbreviations